Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Orgenesis achieves milestone in the placement of the Orgenesis Mobile Processing Units and Lab (OMPUL) for the development of cell and gene therapies at the Hospital OMPULs expected to contribute to...
-
GERMANTOWN, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
-
JV named a “Priority Investment of Strategic National Importance” by the government of GreeceGranted fast-track licensing and approval status GERMANTOWN, Md., Nov. 29, 2021 (GLOBE NEWSWIRE) --...
-
GERMANTOWN, Md., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
-
GERMANTOWN, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
-
GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
-
Goal to accelerate development, QC testing and manufacturing of Orgenesis’ cell and gene therapy platform New assays being developed to potentially enhance the potency of cell and gene therapies for...
-
GERMANTOWN, Md., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
-
GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
-
FDA Pre-IND consultation completed; submission of phase 2 trial of Ranpirnase for anogenital warts on schedule Licensing partner, Okogen, Inc., presented positive interim phase 2 clinical trial...